Regeneron Pharmaceuticals Inc (REGN)

517.93 +0.02  +0.00% NASDAQ Jan 15, 20:00 USD
View Full Chart
Price Chart
View All REGN News

News

View All Events

Events

Date Type Description
02/05/2021 Earnings Regeneron Pharmaceuticals Inc Fourth Quarter Earnings for 2020 Release
02/05/2021 08:00 EST Misc Regeneron Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 08:30 EST Misc Regeneron Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Regeneron Pharmaceuticals Inc Third Quarter Earnings Result for 2020
08/05/2020 08:30 EDT Misc Regeneron Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020
08/05/2020 Earnings Regeneron Pharmaceuticals Inc Second Quarter Earnings Result for 2020
06/12/2020 10:30 EDT Misc Regeneron Pharmaceuticals Inc Annual General Meeting for 2019
05/05/2020 08:30 EDT Misc Regeneron Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Regeneron Pharmaceuticals Inc First Quarter Earnings Result for 2020
02/07/2020 Misc Regeneron Pharmaceuticals Inc Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.regeneron.com
  • Investor Relations URL: http://newsroom.regeneron.com/
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: Feb. 05, 2021
  • Last Earnings Release: Nov. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Top Fund Holders

Symbol Name Weighting
HQL Tekla Life Sciences Investors 6.85%
HQH Tekla Healthcare Investors 6.05%
IBB iShares Nasdaq Biotechnology ETF 4.30%
FSPHX Fidelity® Select Health Care 4.11%
VGHCX Vanguard Health Care Inv 2.95%
USMV iShares MSCI USA Min Vol Factor ETF 1.36%
BMEZ BlackRock Health Sciences Trust II 1.28%
FPUKX Fidelity® Puritan® K 1.16%
ACWV iShares MSCI Global Min Vol Factor ETF 1.14%
CFNFX American Funds Fundamental Invs 529F1 1.13%
FCNKX Fidelity® Contrafund® K 0.93%
CGFFX American Funds Growth Fund of Amer 529F 0.79%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.